A — Customer Relationships that Shape Revenue Visibility and Risk

Agilent (ticker A) operates as an integrated supplier to life sciences, diagnostics and applied markets, monetizing through a mix of capital instrument sales, recurring service and consumable revenue, software licensing/subscriptions, and contract manufacturing (CDMO). This multi‑channel model produces a blend of high‑margin software and services revenue alongside capital‑intensive hardware sales, with measurable remaining performance obligations that support near‑term revenue visibility.

If you want a structured, relationship‑level view that investors use to benchmark counterparty exposure and contract quality, start here: https://nullexposure.com/

How Agilent makes money and what it signals for investors

Agilent’s revenue profile is deliberately diversified across product and service lines. Instruments and consumables drive transactional sales, while services, maintenance, SaaS and licensing produce recurring revenue that increases lifetime customer value and reduces volatility. The company also runs a specialty CDMO and manufacturing arm that ties Agilent more deeply into customers’ supply chains.

Key operating model signals from company disclosures:

• Contracting posture: Agilent reports meaningful remaining performance obligations (RPO) — $437 million as of October 31, 2025 — that reflect longer‑term contracts (extended warranties, manufacturing contracts, software maintenance and lease arrangements), while many service and maintenance agreements are annual. This mix creates a hybrid contract book combining multi‑year visibility with short‑term renewal points.
• Revenue mix and maturity: The business spans hardware, services, software and manufacturing, which balances capital intensity with higher‑margin recurring streams and embeds the firm across customer workflows.
• Counterparty profile and concentration: No single customer represented 10% or more of net revenue in 2025, indicating immaterial customer concentration at the company level.
• Market and geographic reach: Revenue growth is distributed across Americas, EMEA and APAC, and Agilent sells into government and academic markets as well as commercial pharma and industrial end‑markets — a mix that lowers single‑market exposure but raises public‑procurement and compliance considerations.
• Distribution and go‑to‑market: The company sells primarily direct but uses distributors and resellers, which broadens reach at the cost of margin and control over end‑customer relationships.

These signals together show a company with durable contracted revenue backstops, diversified end markets, and embedded service relationships that both stabilize revenue and elevate the strategic importance of select customers and contracts.

Explore tailored counterparty intelligence at https://nullexposure.com/ to quantify these relationships for portfolio due diligence.

Customer relationships, entry by entry

• Keysight Technologies, Inc. — FY2026: $3 million from site service and lease income. Agilent disclosed that the provision of site service costs to, and lease income from, Keysight contributed $3 million in FY2026, indicating a modest commercial relationship tied to site services and lease arrangements (reported in a March 8, 2026 filing reproduced by StockTitan).
  Source: Agilent 10‑Q excerpt (StockTitan reproduction, March 8, 2026).

• Keysight — FY2025: $12 million related to site service and lease income. In the FY2025 Form 10‑K (filed October 31, 2025), Agilent reported $12 million of income related to the provision of site service costs and lease income from Keysight, marking a higher reported contribution the prior fiscal year and illustrating a recurring services/lease revenue line with that counterparty.
  Source: Agilent Form 10‑K (filed Oct 31, 2025).

• TSA — FY2026: $9 million contract for a new instrument. Management stated on the Q1 FY2026 earnings call that a new instrument secured a $9 million TSA contract during the quarter, representing a discrete government procurement tied to equipment sales.
  Source: Q1 FY2026 earnings call transcript (InsiderMonkey, March 8, 2026).

What these relationships say about concentration, criticality and contract maturity

Taken together, the relationship data and company disclosures produce a few clear investor conclusions:

• Concentration is low but pockets of criticality exist. Company‑level disclosure shows no customer exceeding 10% of revenue, so headline concentration risk is immaterial; however, the nature of service and lease arrangements — and discrete government contracts like the TSA award — create pockets where a single counterparty can be operationally critical even if not large in revenue terms.
• Contracts are a mix of long and short commitments. The $437 million RPO and references to extended warranties, manufacturing contracts and software maintenance point to multi‑year commitments that lend near‑term visibility, while annual service agreements and consumable purchases create recurring renewal dynamics.
• Government and non‑profit exposure increase procurement and payment timing risk. The balance of academic, government and health laboratory customers drives stable demand but adds procurement cycles, compliance obligations, and potential payment timing variability.
• Distribution channels diversify reach but dilute control. Use of distributors and resellers accelerates market penetration but reduces direct pricing control and may introduce margin leakage.

Key investor takeaways:

• Strong revenue visibility from contractual backlogs and recurring services.
• Low single‑customer concentration, but strategic relationships (service/lease/CDMO) produce operational stickiness.
• Government contracts and distributor channels create both opportunity and specific execution risks.

If you want to convert these relationship signals into a quantified exposure map for M&A, portfolio monitoring or vendor risk, we provide structured reports that align contract terms and counterparty size: https://nullexposure.com/

Bottom line: where risk and opportunity intersect

Agilent’s customer relationships reflect a disciplined, diversified commercial model that pairs capital equipment sales with higher‑margin recurring services and software licensing. The company’s hybrid contracting posture — long‑dated RPO plus annually renewed services and subscriptions — provides revenue visibility while preserving growth optionality. The principal risks are execution around government procurement, distributor margin pressure, and the capital intensity of the manufacturing/CDMO lines.

For investors and operators, the practical next steps are to track:

• renewal cadence and renewal rates on maintenance/SaaS contracts;
• the composition of RPO over time; and
• the proportion of revenue tied to government procurement versus commercial pharma and academia.

For a deep dive into counterparty exposures and to convert these relationship signals into actionable investment intelligence, visit https://nullexposure.com/ — our platform is built for diligence teams who need granular, relationship‑level clarity.